secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001193125-23-176190
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics amends bylaws and elects three Class II directors at annual meeting
--------------------------------------------------------------------------------

- Board adopted Second Amended and Restated Bylaws effective June 21, 2023, including revised advance notice provisions and universal proxy rule compliance.
- Stockholders elected Meeta Chatterjee, Derek DiRocco, and Daniel Hicklin as Class II directors for three-year terms ending 2026.
- Ratified Ernst & Young as independent auditor for FY2023 with 29,895,437 votes for, 1,400 abstain, 3,279 against.
- Bylaw changes eliminated voting list availability requirement and clarified adjournment procedures per recent DGCL amendments.
- Nominating stockholders soliciting proxies must now use a non-white proxy card.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000119312523176190/0001193125-23-176190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000119312523176190/d506849d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-176190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer